Home Tags CAB-AXL-ADC

Tag: CAB-AXL-ADC

Conditionally Active Biologics (CAB)

What are Conditionally Active Biologics (CABs)?

Conditionally Active Biologics (CABs) are proteins generated using a proprietary protein discovery, evolution and expression technology developed by BioAtla, a global clinical-stage biotechnology company...

First Patient Dosed with AXL-targeted Antibody-drug Conjugate

A first patient has been dosed with BioAtla's BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC). The multi-center, open-label, Phase I/II study called in...

FDA Clears Investigational New Drug application for BA3011, a Novel CAB-AXL-ADC...

The U.S. Food and Drug Administration has cleared the Investigational New Drug Application (IND) for BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC)...

FEATURED RESOURCES